A case of dupilumab-induced psoriasis-like eruption treated with baricitinib.
Skin Health Dis
; 4(2): e338, 2024 Apr.
Article
in En
| MEDLINE
| ID: mdl-38577056
ABSTRACT
Dupilumab is a humanized monoclonal antibody against the interleukin (IL)-4 receptor alpha chain that inhibits IL-4 and IL-13 signalling. It is one of the systemic treatments for patients with moderate-to-severe atopic dermatitis (AD), which provides favourable safety and efficacy. We report a case of psoriasis-like eruption induced by dupilumab as an adverse effect in a patient with AD, immediately remitted after switching to baricitinib, which inhibits JAK1/2. Moreover, the atopic skin lesion also simultaneously went into remission upon baricitinib treatment. Baricitinib could be a favourable option for patients with AD who develop dupilumab-induced psoriasis-like eruption.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Language:
En
Journal:
Skin Health Dis
Year:
2024
Document type:
Article